Introduction {#sec1-0300060519856750}
============

According to a previous report, 1 million patients worldwide benefit from cardiac surgery each year,^[@bibr1-0300060519856750]^ with a 4% incidence of high-risk 30-day mortality.^[@bibr2-0300060519856750]^ Perioperative cardiac ischemia is inevitable in cardiac surgery with or without cardiopulmonary bypass (CPB) and directly causes postoperative myocardial dysfunction and arrhythmia if perioperative CPB is involved. Moreover, reperfusion injury theoretically causes myocardial tissue deterioration, which results in the presence of certain detectable enzymes in the first several days after surgery. Cardiac troponin I (cTnI) is a highly sensitive and specific marker that is used as the gold standard diagnostic marker of myocardial infarction with coronary artery bypass grafting (CABG); cTnI is also a remarkable predictor of the outcomes of cardiac patients.^[@bibr3-0300060519856750][@bibr4-0300060519856750]--[@bibr5-0300060519856750]^ Numerous studies have concluded that an elevated postoperative cTnI level is correlated with morbidity and mortality; additionally, an elevated postoperative cTnI concentration is an independent risk factor for serious outcomes after cardiac surgery, such as a prolonged length of stay in the intensive care unit (ICU) and prolonged hospitalization.^[@bibr6-0300060519856750][@bibr7-0300060519856750][@bibr8-0300060519856750][@bibr9-0300060519856750][@bibr10-0300060519856750][@bibr11-0300060519856750][@bibr12-0300060519856750][@bibr13-0300060519856750]--[@bibr14-0300060519856750]^ In 2004, the American Heart Association/American College of Cardiology first regarded cTnI as a cardiac biomarker for predicting the patient prognosis.^[@bibr15-0300060519856750]^ A meta-analysis also confirmed its prognostic value for all-cause mortality after cardiac surgery.^[@bibr9-0300060519856750]^ cTnI reportedly has the strongest association with mortality at 18 to 24 h after surgery and can predict short-, medium-, and long-term mortality.^[@bibr11-0300060519856750][@bibr12-0300060519856750]--[@bibr13-0300060519856750]^ Hence, if cTnI can be decreased at an early stage postoperatively, then patient outcomes may be effectively improved. Increasingly more clinical studies are now focusing on this issue.

Sevoflurane conditioning is a convenient and applicable strategy in the clinical setting. Sevoflurane protects perioperative organ function against ischemia/reperfusion (I/R) injury via nonanesthetic pharmacological properties. Experimental models have provided strong evidence of the efficacy of sevoflurane postconditioning, and many of the involved signaling pathways or molecular mechanisms have been elucidated.^[@bibr16-0300060519856750][@bibr17-0300060519856750][@bibr18-0300060519856750][@bibr19-0300060519856750][@bibr20-0300060519856750]--[@bibr21-0300060519856750]^ The use of sevoflurane during CPB is associated with reduced peak postoperative troponin levels.^[@bibr22-0300060519856750]^ The related mechanisms induced by postconditioning have been described in detail along with analogous actions in humans,^[@bibr23-0300060519856750]^ such as the generation of reactive oxygen species, actions on mitochondria, and the activation of cellular signaling pathways. Research has confirmed that inhaled anesthetics can provide more long-term benefits than can intravenous anesthetics. Dexmedetomidine (DEX) is a highly specific α^2^-adrenergic agonist that exhibits a broad spectrum of biological activities, including anti-inflammation, signal pathway modulation, and apoptotic and necrotic protection, as well as the ordinary properties applied in clinical anesthesia.^[@bibr24-0300060519856750]^ Numerous animal models have demonstrated the organ-protective effects of DEX against I/R injury^[@bibr25-0300060519856750][@bibr26-0300060519856750][@bibr27-0300060519856750][@bibr28-0300060519856750][@bibr29-0300060519856750][@bibr30-0300060519856750]--[@bibr31-0300060519856750]^ in intestinal, cerebral, myocardial, renal, pulmonary, and hepatic tissues. According to an increasing number of clinical studies,^[@bibr32-0300060519856750][@bibr33-0300060519856750][@bibr34-0300060519856750][@bibr35-0300060519856750][@bibr36-0300060519856750]--[@bibr37-0300060519856750]^ DEX has anti-inflammatory effects and shows remarkable myocardial protection characterized by obvious decreases in cTnI, cardiac troponin T, or creatine kinase isoenzyme MB without severe complications. The mechanism may involve several different signaling pathways such as high-mobility group box 1/Toll-like receptor 4/myeloid differentiation primary response factor 88/nuclear factor kappa-light-chain enhancer of activated B cells (HMGB1/TLR4/MyD88/NF-κB), cyrillic B, mitochondrial adenosine triphosphate-sensitive potassium channel, P38-mitogen activated protein kinase/thioredoxin-interacting protein (P38-MAPK/TXNIP), and 5′-adenosine monophosphate-activated protein kinase/phosphoinositide 3-kinase/protein kinase B/endothelial nitric oxide synthase (AMPK/PI3K/Akt/eNOS).^[@bibr38-0300060519856750]^ Despite its widespread use in clinical practice, DEX has been only occasionally infused during cardiac surgery, especially when sevoflurane postconditioning was popular, and adverse outcomes of its combination use have been seldom reported. We hypothesized that DEX improves the effects of ordinary postconditioning of sevoflurane inhalation. The present study was conducted to confirm the influence of DEX in combination with sevoflurane postconditioning on myocardial injury following cardiac surgery, thus further clarifying the mechanism of sevoflurane postconditioning and improving the current understanding of organ protection by DEX.

Methods {#sec2-0300060519856750}
=======

Study population {#sec3-0300060519856750}
----------------

The ethics committee of the Second Affiliated Hospital of Jiaxing University (tertiary, grade A class, public and teaching hospital) approved this retrospective study and waived the requirement for individual patient consent (JXEY-20180718H01). The present manuscript was written in line with the STROBE checklist for cohort studies. The inclusion criteria were the performance of cardiac surgery (mitral valve, tricuspid valve, and aortic valve surgeries) from 1 April 2016 to 30 April 2017 in the Second Affiliated Hospital of Jiaxing University; an age of \>18 years; the absence of dramatic perioperative hemodynamic changes; and successful discharge from the hospital. The exclusion criteria were emergency surgery; New York Heart Association (NYHA) class IV heart failure; incomplete cTnI data (measured every 6 h after surgery in our unit); and coronary heart disease, perioperative coronary embolism, or a pre-existing high cTnI level (≥0.2 ng/ml).^[@bibr39-0300060519856750]^ The patients' baseline characteristics (age, sex, body mass index, left ventricular ejection fraction, NYHA class, type of surgery needed, preoperative medications, and coexisting disease), surgical procedure details (CPB time, cross-clamping time, cardioplegia dosage, and cardiac cardioversion), and perioperative cTnI levels were recorded by browsing the Medical Anesthesia Information System (primarily consisting of information on intraoperative data before ICU admission) and the Resident Information Service System (which included all electronic data from the operating room, as well as the ward and ICU data). The abovementioned variables were also chosen as potential confounders for the multiple regression analysis. After exclusion of ineligible patients, consecutive eligible patients were assigned to two groups: the non-DEX group (only sevoflurane postconditioning; this strategy was used in an ongoing clinical study) and the DEX group (DEX infusion was administered based on sevoflurane postconditioning). Electronic data were collected from the abovementioned databases by an independent inspector. Because this study was retrospective, no *a priori* statistical power analysis calculation was used to guide the sample size.

General anesthesia was induced with midazolam (average of 0.1 mg/kg), etomidate (average of 0.3 mg/kg), lidocaine (average of 0.5 mg/kg), sufentanil (average of 1 µg/kg), and rocuronium (average 0.6 mg/kg). Phenylephrine (20-µg single injection in our unit) was used intermittently to manage fluctuations in blood pressure. Ventilation parameters were adjusted to an end-tidal carbon dioxide pressure of 35 to 45 mmHg. Arteriovenous catheterization and transesophageal echocardiography were usually applied for hemodynamic and cardiac functional monitoring. DEX infusion was performed between intubation and the beginning of CPB; the specific dose was determined by an anesthesiologist, with a defined use of 0.2 to 0.7 μg/kg/h in our unit. The vasoactive drugs used during surgery included adrenaline, nitroglycerin, norepinephrine, and dopamine. The CPB apparatus used was equipped with oxygenators and a circuit used for cold blood cardioplegia (MAQUET, Rastatt, Germany). The acid--base balance was guaranteed under medium hypothermic CPB. Sevoflurane inhalation was provided through a Dräger vaporizer (Drägerwerk AG, Lübeck, Germany) attached to the oxygenator, started at approximately the same time as aortic declamping, and continued for approximately 20 min. A sevoflurane minimum alveolar concentration of 2.0 was maintained during postconditioning. Anesthesia maintenance was based on the combination of propofol and sufentanil, with the aim of maintaining a bispectral index of 40 to 60. After surgery, the patients were transferred to the ICU and sedated with propofol or sufentanil as required. The dose was controlled by the ICU physician.

The cTnI measurements were collected from an electronic database. The cTnI level was examined every 6 h for the first 24 h after surgery using an enzyme-linked immunosorbent assay kit (Life Diagnostics, West Chester, PA, USA) according to the manufacturer's protocol. All available parameters for anesthetic and vasoactive agents were recorded from the perioperative procedure database. Perioperative hemodynamic data (mean arterial pressure, heart rate, cardiac index, and central venous pressure) were also recorded before induction, before CPB, 2 h after CPB, and 24 h after CPB.

The primary endpoint of this study was the peak cTnI level, which was defined as the highest average level among those determined at different time points. The following postoperative outcomes and complications were also reported: the length of ICU stay, time to extubation, length of hospital stay, and occurrence of renal failure, sepsis, and reoperation for bleeding.

Statistical methods {#sec4-0300060519856750}
-------------------

Continuous variables are expressed as mean ± standard deviation or median and interquartile range as appropriate. Categorical and rank variables are expressed as count (percentage). SPSS Statistics for Windows, Version 17.0 (SPSS Inc., Chicago, IL, USA) was used to conduct independent t-tests or chi-squared tests for continuous or categorical variables, and the Mann--Whitney U test was applied for non-normally distributed continuous variables. Linear regression was used with the univariate model. A stepwise method of multiple linear regression analysis was utilized to assess the associations between univariate factors and the peak cTnI level. Repeated-measures analysis of variance was applied to hemodynamic data and cTnI comparisons at different time points. All reported p values were two-sided, and p values of \<0.05 were considered significant.

Results {#sec5-0300060519856750}
=======

Baseline and perioperative data {#sec6-0300060519856750}
-------------------------------

The study population comprised 100 patients (non-DEX group, n = 47; DEX group, n = 53). Demographic and preoperative data of all included patients are presented in [Table 1](#table1-0300060519856750){ref-type="table"}. After screening, fully integrated data were found at only four time points for both groups. No significant differences were found in sex, body mass index, baseline cTnI level, creatine kinase isoenzyme MB level, creatinine level, left ventricular ejection fraction, NYHA class, surgery type, preoperative medication, coexisting diseases, cardioplegia dosage, surgery time, length of ICU stay, or extubation time between the two groups. Patients in the DEX group were older than those in the non-DEX group; moreover, lower cTnI levels and fewer instances of cardiac cardioversion were found in the non-DEX group (p \< 0.01) ([Table 1](#table1-0300060519856750){ref-type="table"}).

###### 

Demographic and perioperative data in both groups.

![](10.1177_0300060519856750-table1)

  Variables                      Non-DEX group (n=47)   DEX group (n=53)   p-value
  ------------------------------ ---------------------- ------------------ ------------
  Age, years                                                               
   Median (IQR)                  46 (29)                57 (21)            0.041\*
  Sex                                                                      
   Female                        22 (47)                30 (57)            
   Male                          25 (53)                23 (43)            0.328
  BMI, kg/m^2^                                                             
   Median (IQR)                  24 (13)                26 (11)            0.609
  Baseline cTnI, ng/mL                                                     
   Median (IQR)                  0.08 (0.079)           0.07 (0.060)       0.709
  Average highest cTnI, ng/mL                                              
   Median (IQR)                  16.5 (5.4)             13.4 (5.8)         \<0.01\*\*
  CK-MB, U/L                                                               
   Median (IQR)                  24 (9)                 24 (7)             0.461
  Creatinine level, μmol/L                                                 
   Median (IQR)                  87 (37)                77 (43)            0.785
  Coexisting diseases                                                      
   Hypertension                  43 (91)                45 (85)            0.312
   Diabetes                      12 (26)                8 (15)             0.193
   Renal failure                 3 (6)                  2 (4)              0.550
   Pulmonary hypertension        12 (26)                10 (19)            0.422
   Atrial fibrillation           6 (13)                 9 (17)             0.556
   Congestive heart failure      4 (9)                  3 (6)              0.577
   Hypertrophic cardiomyopathy   0 (0)                  1 (2)              0.344
   Sepsis                        1 (2)                  0 (0)              0.286
  LVEF                                                                     
   ≥50%                          31 (66)                39 (74)            
   \<50%                         16 (34)                14 (26)            0.406
  NYHA classification                                                      
   I                             6 (13)                 10 (19)            
   II                            28 (59)                32 (60)            
   III                           13 (28)                11 (21)            0.305
  Surgery type                                                             
   1 valve                       10 (21)                9 (17)             0.585
   2 valves                      22 (47)                24 (45)            0.879
   3 valves                      15 (32)                20 (38)            0.542
  Preoperative medication                                                  
   ACEI                          6 (13)                 8 (15)             0.738
   Beta blocker                  10 (21)                15 (28)            0.418
   Calcium blocker               1 (2)                  2 (4)              0.630
   Nitrate drug                  2 (4)                  3 (6)              0.748
   Diuretic                      46 (98)                51 (96)            0.630
   Spironolactone                46 (98)                51 (96)            0.630
   Digoxin                       18 (38)                20 (38)            0.954
  Perioperative parameters                                                 
  Blood transfusion                                                        
   Yes                           34 (72)                43 (81)            
   No                            13 (28)                10 (19)            0.297
  CPB time                                                                 
   ≥120 minutes                  16 (34)                23 (43)            
   \<120 minutes                 31 (66)                30 (57)            0.339
  Cross-clamping time                                                      
   ≥60 minutes                   30 (64)                34 (64)            
   \<60 minutes                  17 (36)                19 (36)            0.973
  Cardioplegia dosage                                                      
   ≥25 ml/kg                     33 (70)                38 (72)            
   \<25 ml/kg                    14 (30)                15 (28)            0.870
  Cardiac cardioversion                                                    
   Yes                           36 (77)                29 (55)            
   No                            11 (23)                24 (45)            0.022\*

Data are presented as median (IQR) for continuous variables and n (%) for categorical data. BMI, body mass index; cTnI, cardiac troponin I; CK-MB, creatine kinase isoenzyme MB; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; ACEI, angiotensin-converting enzyme inhibitors; CPB, cardiopulmonary bypass; DEX, dexmedetomidine. \*p\<0.05, \*\*p\<0.01.

DEX was injected at an average infusion rate of 0.5 µg/kg/h, and the overall amount was 28 µg (interquartile range, 13 µg). The doses of sufentanil (118±19 vs. 183±26 µg) and propofol (1243±104 vs. 1754±143 mg) were markedly lower in the DEX than non-DEX group (p \< 0.01), but these dose differences were not associated with the cTnI level. There were no differences in sevoflurane or midazolam consumption between the two groups. We could not calculate the use of vasoactive drugs because of the variation of use of these drugs in the ICU according to the patients' different needs.

The perioperative hemodynamic data (mean arterial pressure, heart rate, cardiac index, and central venous pressure) are shown in [Table 2](#table2-0300060519856750){ref-type="table"}, and the postoperative outcomes and complications are shown in [Table 3](#table3-0300060519856750){ref-type="table"}. No obvious differences were found between the DEX and non-DEX groups.

###### 

Perioperative hemodynamic data in both groups.

![](10.1177_0300060519856750-table2)

                     Before induction   Before CPB   2 hours after CPB   24 hours after CPB   
  ------------------ ------------------ ------------ ------------------- -------------------- --
  MAP, mmHg                                                                                   
   DEX group         90±18              69±12\*      80±17\*             93±24                
   Non-DEX group     91±20              71±10\*      83±21               92±21                
  HR, beats/minute                                                                            
   DEX group         86±13              75±12\*      90±24               95±24\*              
   Non-DEX group     82±15              77±11        93±25\*             93±26\*              
  CVP, mmHg                                                                                   
   DEX group                            9±2          8±3                 7±3^\#^              
   Non-DEX group                        10±3         9±3                 8±3^\#^              
  CI, L/min/m^2^                                                                              
   DEX group                            3.58±0.75    2.78±0.54^\#^       3.49±0.82            
   Non-DEX group                        3.40±0.78    2.74±0.65^\#^       3.25±0.75            

Values are presented as mean ± standard deviation. DEX, dexmedetomidine; CPB, cardiopulmonary bypass; MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure; CI, cardiac index. \*p\<0.05 compared with before induction; ^\#^p\<0.05 compared with before CPB.

###### 

Postoperative outcomes and complications in both groups.

![](10.1177_0300060519856750-table3)

  Variables                         Non-DEX group (n=47)   DEX group (n=53)   p-value
  --------------------------------- ---------------------- ------------------ ---------
  Length of ICU stay, days          34 (10)                33 (7)             0.214
  Time to extubation, hours         22 (14)                21 (9)             0.174
  Length of hospital stay, days     10 (4)                 11 (3)             0.309
  Renal failure (n, %)              4 (8)                  5 (9)              1.000
  Sepsis (n, %)                     2 (4)                  2 (4)              1.000
  Reoperation for bleeding (n, %)   3 (6)                  2 (4)              0.664

Values are presented as median (interquartile range) for continuous variables and n (%) for categorical data. DEX, dexmedetomidine; ICU, intensive care unit. \*p\<0.05, \*\*p\<0.01.

Univariate analysis of peak cTnI level in both groups {#sec7-0300060519856750}
-----------------------------------------------------

In the univariate linear regression model, which included age, NYHA class, CPB time, cross-clamping time, cardiac cardioversion, DEX use, and cTnI level, dependent variables (NYHA class, CPB time, and DEX use) had a potential influence on the induced variables (p \< 0.01) ([Table 4](#table4-0300060519856750){ref-type="table"}). For each unit increase in the NYHA class and CPB time, the cTnI level increased by 1.436 and 0.035 ng/ml, respectively. Conversely, the cTnI level was 4.035 ng/ml lower in the DEX than non-DEX group (p \< 0.01).

###### 

Linear regression models (univariate) to identify the associations with the cTnI level.

![](10.1177_0300060519856750-table4)

  Variables                       R^2^    B        p-value
  ------------------------------- ------- -------- -----------
  Age (years)                     0.015   −0.033   0.224
  NYHA class (I, II, III)         0.042   1.436    0.040\*
  CPB time (minutes)              0.053   0.035    0.021\*
  Cross-clamping time (minutes)   0.013   0.020    0.264
  Cardioversion (yes, no)         0.018   1.219    0.188
  DEX use (yes, no)               0.211   −4.035   \<0.001\*

cTnI, cardiac troponin I; NYHA, New York Heart Association; CPB, cardiopulmonary bypass; DEX, dexmedetomidine. \*p\<0.1.

Multivariable analysis of peak cTnI level in both groups {#sec8-0300060519856750}
--------------------------------------------------------

Among the meaningful influential variables found in the univariable analysis, the NYHA class, DEX use, and CPB time were included in the regression model. The established regression equation was significant (F(3,96) = 12.582, p \< 0.01) through elimination of the NYHA class (B = 0.780), but lost significance in the multivariate linear regression model (R = 0.531, R^2^ = 0.282, adjusted R^2^ = 0.26) ([Table 5](#table5-0300060519856750){ref-type="table"}). DEX use and CPB time were independent factors that contributed to cTnI changes (DEX use: B = −4.097; 95% confidence interval, −5.609 to −2.584, p \< 0.01 and CPB time: B = 0.038; 95% confidence interval, 0.011--0.064; p \< 0.01). Moreover, the use of DEX exerted a more significant influence on the cTnI level than did the CPB time (standardized B for DEX and CPB time, −0.466 and 0.244, respectively). DEX decreased the cTnI level by 4.097 µmol/L when we controlled for other dependent variables.

###### 

Results of multivariable linear models for potential factors influencing the cTnI level.

![](10.1177_0300060519856750-table5)

               Unstandardized   Standardized            95% CI of B            
  ------------ ---------------- -------------- -------- ------------- -------- --------
  Constant     11.573           1.839                   \<0.001\*     9.923    15.222
  DEX          −3.989           0.765          −0.454   \<0.001\*     −5.507   −2.471
  CPB time     0.034            0.014          0.220    0.015\*       0.007    0.061
  NYHA class   0.780            0.622          0.112    0.213         −0.455   2.015

cTnI, cardiac troponin I; CI, confidence interval; DEX, dexmedetomidine; CPB, cardiopulmonary bypass; NYHA, New York Heart Association; Std error, standard error. The independent variables are DEX and CPB. The dependent variable is the cTnI level. A negative standardized beta value indicates that the use of DEX is associated with a lower cTnI level. \*p\<0.05.

Stratification analysis of both groups {#sec9-0300060519856750}
--------------------------------------

Over time, the cTnI level showed significant fluctuations in both groups (p \< 0.01) ([Figure 1](#fig1-0300060519856750){ref-type="fig"}). The peak cTnI level appeared at approximately 12 h after surgery. DEX use had an interactive influence on the cTnI level at every time point (p \< 0.01). Based on the multivariate analysis of variance, the cTnI levels at 6, 12, and 24 h after surgery were significantly lower in the DEX than non-DEX group (p \< 0.01, p \< 0.01, and p = 0.020, respectively) ([Table 6](#table6-0300060519856750){ref-type="table"}).

![cTnI values at different time points after surgery. DEX, dexmedetomidine; Non-DEX, without dexmedetomidine; cTnI, cardiac troponin I; T1, end of surgery; T2, 6 hours after surgery; T3, 12 hours after surgery; T4, 24 hours after surgery. The line chart with bar shows the mean ± standard deviation. \*p=0.028, \#p\<0.01.](10.1177_0300060519856750-fig1){#fig1-0300060519856750}

###### 

cTnI levels at different time points.

![](10.1177_0300060519856750-table6)

  Time points   D group      C group      C-D value   p-value     95% CI
  ------------- ------------ ------------ ----------- ----------- -------------
  T1            5.87±2.64    6.75±1.75    0.88±0.46   0.055       −0.21, 1.78
  T2            9.60±3.10    10.74±1.77   1.14±0.51   0.028\*     0.12, 2.16
  T3            12.65±4.13   20.48±6.95   7.83±1.13   0.000\*\*   5.59, 10.07
  T4            8.38±2.76    14.24±7.80   5.86±1.80   0.002\*\*   2.28, 9.44

Values are presented as mean ± standard deviation. D group, DEX group; C group, non-DEX group; C-D value, difference between the C and D groups; CI, confidence interval; T1, end of surgery; T2, 6 hours after surgery; T3, 12 hours after surgery; T4, 24 hours after surgery. \*p\<0.05, \*\*p\<0.01.

Discussion {#sec10-0300060519856750}
==========

In the present study, DEX infusion was correlated with changes in the cTnI level after valve replacement surgery with sevoflurane postconditioning. Additionally, DEX infusion led to decreased cTnI levels. DEX infusion may protect against myocardial injury at 6, 12, and 24 h after cardiac valve surgery.

Elevated cTnI levels have always been associated with adverse outcomes and poor short- and mid-term survival.^[@bibr6-0300060519856750],[@bibr9-0300060519856750]^ Despite the high sensitivity and specificity of cTnI, the underlying cause of elevated cardiac cTnI levels after cardiac surgery has generally remained unclear because of the lack of high-throughput assay standardization, confounding factors, or high variation among different studies, such as the timing of testing and confounding diseases. Thus far, the specific mechanism remains unknown. Identifying the cause of these elevated levels and establishing precise methods with which to address this dilemma are urgently needed. In the present study, we adopted the highest average cTnI level as the primary outcome instead of the cTnI level at a single time point to avoid confounding factors.

CPB and aortic cross-clamping trigger I/R injury in cardiac surgery. "Conditioning" the myocardium may be an effective solution. Sevoflurane postconditioning, a form of pharmacological conditioning, exhibits the same efficacy as ischemic conditioning. Several clinical studies and meta-analyses have demonstrated the contribution of a potential cardioprotective strategy by sevoflurane postconditioning.^[@bibr17-0300060519856750],[@bibr22-0300060519856750],[@bibr23-0300060519856750],[@bibr40-0300060519856750]^ Related fundamental research assumed the involvement of the protein kinase C, PI3K/Akt, and extracellular signal-related kinase 1/2 pathways.^[@bibr23-0300060519856750]^ The safety and efficacy of DEX in perioperative cardiac surgery have been confirmed.^[@bibr24-0300060519856750]^ Furthermore, the organ-protective characteristics of DEX have been verified by an increasing number of studies in which the signaling pathways are the same as those influenced by sevoflurane.^[@bibr41-0300060519856750],[@bibr42-0300060519856750]^ However, not every study has shown advantages; one study revealed important abnormalities, such as bradycardia or hypotension,^[@bibr34-0300060519856750]^ that were mostly caused by DEX infusion of different loading and maintenance doses. Additionally, in a study by Chi et al.,^[@bibr43-0300060519856750]^ the extubation time and length of stay were prolonged in patients who underwent off-pump CABG with high-dose DEX infusion (loading dose, 1 μg/kg; maintenance dose, 0.6 μg/kg/h) despite significant cardiac protection. Thus, DEX can enhance the protective effect if an appropriate dose or complex strategy is applied, such as sevoflurane "conditioning." For this reason, we applied DEX preconditioning combined with sevoflurane "conditioning" in the present study.

The influencing factors that lead to cardiac injury range from anesthetic factors to operative factors. In the present study, the CPB time, NYHA class, and DEX use were all correlated with myocardial injury. As the only meaningful anesthetic factor in this study, DEX was negatively correlated with the cTnI level (r = −0.454, p \< 0.001), and this was actually equivalent to the well-known myocardial protection of DEX in cardiac surgery.^[@bibr24-0300060519856750],[@bibr44-0300060519856750]^ Based on entering or removing the probability of F≤0.05 and F≥0.100, both DEX use and the CPB time contributed to the occurrence of myocardial injury in the multivariable analysis, and DEX use was a greater contributor to myocardial injury (0.454\>0.220).

To the best of our knowledge, the present study is the first to reveal the influence of DEX preconditioning on sevoflurane postconditioning in cardiac surgery. cTnI was selected as the only outcome with which to predict myocardial injury and was measured at 6-h intervals after surgery in our hospital. The average peak cTnI level was 14.7 ng/ml at approximately 12 to 24 h after surgery, indicating obvious myocardial injury, despite the contributions of multiple factors. This result is similar to the results reported by Croal et al.,^[@bibr13-0300060519856750]^ who analyzed many different factors involved in myocardial injury in patients undergoing cardiac surgery and detected extremely elevated cTnI levels 24 h after CPB. In a study by Shen et al.,^[@bibr32-0300060519856750]^ lower cTnI levels were observed following DEX intervention at 48 h after surgery than following the control intervention; the 48-h postsurgery cTnI levels were also lower than the 24-h postsurgery cTnI levels. Studies by Sedighinejad et al.^[@bibr45-0300060519856750]^ and Chi et al.^[@bibr43-0300060519856750]^ also indicated that DEX significantly decreased the cTnI level after CABG surgery. Compared with the abovementioned outcomes, the protective events against cardiac injury appeared sooner in our study than in other studies, although different surgical backgrounds and DEX usages were found in some studies. Furthermore, compared with non-DEX use, DEX infusion decreased the average cTnI level by approximately 4 ng/ml (p \< 0.001), and the greatest decrease was 7.8 ng/ml at 12 h after surgery. A similar trend of the changes in cTnI at different time points in the DEX group was observed in a study by Chen et al.,^[@bibr36-0300060519856750]^ in which CABG under CPB was carried out and DEX was infused throughout the entire surgical period. Thus, the difference in surgery type and DEX use resulted in a further decrease in cTnI, but the consequence was identical to that in the current study.

Generally, the peak cTnI concentration, which depends on the type of surgery or the subsequent degree of myocardial trauma, is most often observed 24 h after CPB, regardless of other factors. In the present study, the peak cTnI level appeared 12 h after CPB, which differs from the results of the study by Croal et al.^[@bibr13-0300060519856750]^ This difference may be due to the recruitment of patients who underwent valve surgery only; the direct result was a higher cTnI concentration observed sooner after valve surgery than after CABG or other surgery types.

Another risk factor that led to high cTnI levels was the CPB time, which is the main cause of myocardial injury in surgery and is similar to the conclusion regarding risk factors reported by Paparella et al.,^[@bibr6-0300060519856750]^ showing that a long CPB time is one of the contributors to myocardial damage.

Nonetheless, the present study had several limitations. First, additional outcome variables were not studied. Moreover, DEX intervention has not been confirmed as an independent influencing factor; thus, further research is warranted. Second, the sample size was small, and the peak cTnI level served as the only parameter. In other studies, the cTnI level varied among different valve surgeries, and some evidence even indicated that no apparent effect was observed in some types of valve surgery. Therefore, a subgroup analysis in terms of different surgeries is needed in future studies. Third, this study contained selection bias due to the DEX dosage and utility time, which were determined by the anesthetist. Therefore, future studies should highlight the influence of these factors on related outcomes. These factors will be further explored in future research if the plasma concentration of DEX is considered. Finally, there was no subgroup analysis of the effect of different doses of DEX on the outcome.

Conclusion {#sec11-0300060519856750}
==========

In conclusion, we found a significant decrease in myocardial injury at 6, 12, and 24 h after valve replacement surgery when DEX was infused with sevoflurane postconditioning. However, more prospective, multicenter, randomized controlled trials are needed to verify the reliability of these results and mechanisms.
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